Hologic (NASDAQ:HOLX) Price Target Cut to $70.00 by Analysts at Citigroup

Hologic (NASDAQ:HOLX) had its target price decreased by Citigroup from $80.00 to $70.00 in a research report sent to investors on Tuesday morning,Benzinga reports. Citigroup currently has a neutral rating on the medical equipment provider’s stock.

A number of other equities analysts have also recently weighed in on HOLX. Leerink Partnrs cut Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. Leerink Partners lowered Hologic from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $80.00 to $75.00 in a research report on Thursday, February 6th. BNP Paribas upgraded Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Morgan Stanley decreased their price objective on Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Finally, Needham & Company LLC downgraded Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price for the company. in a research report on Monday, February 3rd. Eleven research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Hologic currently has an average rating of “Hold” and a consensus target price of $84.62.

Hologic Stock Down 1.5 %

HOLX stock opened at $62.30 on Tuesday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The company has a market capitalization of $13.98 billion, a price-to-earnings ratio of 19.65, a PEG ratio of 2.14 and a beta of 0.97. Hologic has a fifty-two week low of $62.28 and a fifty-two week high of $84.67. The stock has a fifty day moving average of $68.77 and a 200-day moving average of $75.64.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, equities research analysts predict that Hologic will post 4.28 earnings per share for the current year.

Institutional Investors Weigh In On Hologic

Several hedge funds have recently modified their holdings of HOLX. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Hologic during the fourth quarter valued at about $28,269,000. Jefferies Financial Group Inc. increased its holdings in shares of Hologic by 141.5% during the fourth quarter. Jefferies Financial Group Inc. now owns 96,849 shares of the medical equipment provider’s stock valued at $6,982,000 after acquiring an additional 56,742 shares in the last quarter. Forum Financial Management LP purchased a new stake in Hologic during the 4th quarter worth approximately $324,000. Toronto Dominion Bank grew its position in Hologic by 7.9% during the 4th quarter. Toronto Dominion Bank now owns 124,308 shares of the medical equipment provider’s stock worth $8,961,000 after purchasing an additional 9,076 shares during the last quarter. Finally, North Star Asset Management Inc. grew its position in Hologic by 0.3% during the 4th quarter. North Star Asset Management Inc. now owns 252,857 shares of the medical equipment provider’s stock worth $18,228,000 after purchasing an additional 687 shares during the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.